Going From Proof of Concept Funding to $65 Mil in Series B Funding

Taligen Therapeutics, Inc. was founded in March 2004 to develop and commercialize technology developed by UC Denver’s Dr. V. Michael Holers for the treatment of serious inflammatory disease. Larry talked with Dr. Holers and Dr. Woodruff Emlen, MD co-founder, President, CEO and Director of Taligen. Taligen received its initial impetus through receipt of the inaugural grant in CU TTO’s Proof of Concept Grant (POCg) Program in 2004 and subsequently, SBIR grants. In August 2005 Taligen received its Series A financing of $3.75M led by Sanderling Ventures, Tango and High Country Venture. On Feb. 1, 2008 the company announced the closing of a $65M Series B financing. Formerly, Dr. Emlen [was at the University of Colorado] and Dr. Holers are a wonderful example of how industry and the academic world can team up to build a business that will benfit humanity. They both appreciate the work and support they get from CU TTO. Taligen is developing technologies to manipulate complement proteins of the immune system to inhibit inflammation and to target inhibitors of inflammation to specific sites of tissue injury; the initial disease targets are macular degeneration and asthma. Listen  Related Links: Taligen Therapeutics || CU Tech Transfer Offices || CU TTO Channel || Find It || - Bytes: 11510912

- More Stories on w3w3.com Colorado's Voice of the Technology and Business Community!